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Soluble OX40L and JAG1 Induce 
Selective Proliferation of Functional 
Regulatory T-Cells Independent of 
canonical TCR signaling
Prabhakaran Kumar1, Khaled Alharshawi1, Palash Bhattacharya1, Alejandra Marinelarena1, 
Christine Haddad1, Zuoming Sun2, Shigeru Chiba3, Alan L. Epstein4 & Bellur S. Prabhakar1
Regulatory T-cells (Tregs) play a pivotal role in maintaining peripheral tolerance. Increasing Treg 
numbers/functions has been shown to ameliorate autoimmune diseases. However, common Treg 
expansion approaches use T-Cell Receptor (TCR)-mediated stimulation which also causes proliferation 
of effector T-cells (Teff). To overcome this limitation, purified patient-specific Tregs are expanded ex vivo 
and transfused. Although promising, this approach is not suitable for routine clinical use. Therefore, an 
alternative approach to selectively expand functional Tregs in vivo is highly desired. We report a novel 
TCR-independent strategy for the selective proliferation of Foxp3+Tregs (without Teff proliferation), 
by co-culturing CD4+ T-cells with OX40 L+Jagged(JAG)-1+ bone marrow-derived DCs differentiated 
with GM-CSF or treating them with soluble OX40 L and JAG1 in the presence of exogenous IL-2. Tregs 
expanded using soluble OX40 L and JAG1 were of suppressive phenotype and delayed the onset of 
diabetes in NOD mice. Ligation of OX40 L and JAG1 with their cognate-receptors OX40 and Notch3, 
preferentially expressed on Tregs but not on Teff cells, was required for selective Treg proliferation. 
Soluble OX40L-JAG1-induced NF-κB activation as well as IL-2-induced STAT5 activation were essential 
for the proliferation of Tregs with sustained Foxp3 expression. Altogether, these findings demonstrate 
the utility of soluble OX40 L and JAG1 to induce TCR-independent Treg proliferation.
Regulatory T-cells (Treg) area specialized subset of T-cells which play pivotal role in suppressing self-reactive 
effector T-cells (Teff) and thereby help maintain the critical balance between self-tolerance and autoimmun-
ity1. Depletion of Foxp3+ Tregs in mice leads to multi-organ autoimmunity2,3. Similarly, patients with IPEX 
(Immunodysregulation, Polyendocrinopathy, Enteropathy, X-linked syndrome) characterized by mutations in 
FOXP3 gene suffer from multiple autoimmune diseases4,5. Restoration of functional Treg cell numbers can aid 
in the recovery from various experimental autoimmune diseases such as experimental encephalomyelitis6 and 
type-1 diabetes (T1D)7. However, translating these experimental Treg therapies into clinical practice has been 
challenging. Current Treg expansion protocols involve the use of anti-CD3/CD28 which can also cause concom-
itant expansion of Tconv/Teff cells thus limiting its utility for in vivo application8,9. To circumvent this limitation, 
highly purified Tregs are expanded ex vivo and then infused back into the patients. This process is cumbersome 
and requires good manufacturing practice (GMP) facility. Such an approach is also not suitable for routine clin-
ical use. Moreover, ex vivo expansion of Tregs by repeated TCR stimulation can lead to CpG methylation within 
the Foxp3 gene locus resulting in loss of Foxp3 expression 10,11. Moreover, it is likely that upon adoptive transfer 
the ex vivo expanded Tregs might not only lose their Foxp3 expression, but may morph into a labile/plastic phe-
notype that produce pro-inflammatory cytokines12. Therefore, an alternative approach that can cause selective 
proliferation of functional Tregs, and not Teff cells, with sustained Foxp3 expression is highly desired.
Tregs differ from Tconv cells in several aspects including their activation, proliferation and function. During 
the steady state, upon maturation in the thymus, Tregs with self-antigen specific TCRs are positively selected and 
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migrate to the periphery13–15. In the periphery they undergo proliferation upon interaction with dendritic cells 
(DCs) through their TCR16,17 while receiving survival signal from IL-218,19. Tregs constitutively express genes such 
as Ctla-4, Cd39 and Helios, which are associated with suppressive functions20. Furthermore, Tregs can suppress 
Teff function irrespective of their antigen specificity as well21,22. Therefore, Tregs expanded by TCR-independent 
methods can still retain their suppressive functions and will have significant clinical utility.
We and others have previously shown that Foxp3+ Treg proliferation, independent of TCR stimulation, can 
be induced by co-culturing them with a particular subset of dendritic cells (DCs)23–28. Bone marrow (BM) pre-
cursor cells differentiated in the presence of GM-CSF (G-BMDCs), upon co-culture with CD4+ T-cells, caused 
Treg proliferation mediated through OX40L-JAG1 co-signaling23. In the present study, we demonstrate that sol-
uble OX40 L and JAG1 along with IL-2 were sufficient to cause Treg proliferation in the absence of TCR stim-
ulation. Unlike TCR-stimulation approach, OX40L-JAG1 caused selective proliferation of Tregs with little or 
no proliferation of Teff cells. OX40L-JAG1 expanded Tregs were of a stable-suppressive phenotype and func-
tionally competent. Furthermore, treatment of NOD mice with soluble OX40 L and JAG1 increased Tregs and 
delayed the onset of hyperglycemia in NOD mice. Using OX40 and Notch3 deficient mice, we showed that 
this TCR-independent Treg expansion was critically dependent on the signaling mediated through these cog-
nate receptors for OX40 L and JAG1 respectively. Signaling studies revealed that NF-κ B activation induced by 
OX40L-OX40 and JAG1-Notch3 interactions, and STAT5 induced by IL-2, were essential for Treg proliferation 
with sustained Foxp3 expression. Thus, we report a novel “TCR-independent” strategy for the selective expansion 
of functional Tregs which could have therapeutic implications in various autoimmune diseases including T1D.
Results
G-BMDCs-induced Treg proliferation is mediated through OX40L-JAG1 co-signaling in NOD 
mice and soluble OX40L-JAG1 are sufficient to cause Treg proliferation in the presence of IL-2. 
Upon co-culturing total CD4+ T-cells with splenic (SpDCs) and G-BMDCs from NOD mice for 5 days, we 
observed a significant (***p < 0.001) increase in selective Treg proliferation in G-BMDC co-cultures compared 
to co-cultures with SpDCs (Fig. 1A,B). To determine whether OX40 L and JAG1 co-signaling is involved in this 
G-BMDCs induced Treg proliferation, we pre-treated G-BMDCs with blocking antibodies against OX40 L, JAG1, 
neurolpilin and ligand for glucocorticoid-induced TNFR family related protein (GITRL) and then co-cultured 
with total CD4+ T-cells. We observed a significant reduction in Treg proliferation in the presence of blocking 
antibodies to OX40 L (**p < 0.01) and JAG1 (**p < 0.01) but not GITRL or neuropilin. This underscored the 
specific involvement of OX40 L and JAG1 signaling in G-BMDCs-induced Treg proliferation from NOD mice 
(Fig. 1C,D). To confirm the involvement of Notch signaling induced by JAG1, we pre-treated CD4+ T-cells with 
γ -secretase inhibitor (GSI) to inhibit Notch signaling and co-cultured with G-BMDCs. As shown in Fig. S1A, 
we found a dose-dependent inhibition of Treg proliferation indicating the critical role of Notch signaling. 
Among the various Notch receptors, Notch3 is preferentially over-expressed on Tregs when compared to Teff 
cells29. Therefore, we sorted for Notch3−OX40−, Notch3+OX40 L−, Notch3−OX40+, Notch3+OX40+ subsets of 
CD4+CD25+ Tregs from NOD mice and co-cultured them with G-BMDCs. The G-BMDC-induced proliferation 
was maximal in Notch3+OX40+ Tregs compared to Notch3+ OX40- and Notch3-OX40+ Treg subsets (Fig. S1B). 
Next, we checked whether soluble OX40 L and JAG1 were sufficient to cause proliferation of Tregs. We treated 
CD4+ T-cells with soluble OX40 L and JAG1 in the presence of IL-2 without any exogenous antigenic stimula-
tion for 3 days. Since we anticipated OX40L-JAG1 treatment not to cause Teff cell activation, exogenous IL-2 
was added to maintain Treg survival in ex vivo cultures. As shown in Fig. 2C,D, among the different combi-
nations tested OX40L-JAG1-IL-2 treatment caused maximum increase in the percentage of proliferating Tregs 
(**p < 0.01) followed by OX40L-IL-2 and JAG1-IL-2. Further, CD4+ T-cells treated with IL-2 alone or OX40L-
JAG1-IL-2 were stained for proliferation marker Ki67 and percentage of Ki67+ Tregs were found to be more in 
OX40L-JAG1-IL-2 treated cells compared to IL-2-treated controls (Fig. S2). Taken together, these results showed 
that soluble OX40 L and JAG1 were sufficient to cause Treg proliferation independent of TCR stimulation in an 
IL-2 dependent manner.
Soluble OX40L- JAG1-IL-2 can cause selective proliferation of Tregs independent of TCR stimu-
lation. To validate whether OX40L-JAG1-induced Treg proliferation differs from TCR-stimulation approach, 
we compared the T-cell proliferation induced by TCR-dependent anti-CD3-CD28 versus TCR-independent 
OX40L-JAG1 stimulation. As shown in Fig. 2A, we observed robust proliferation of Tregs upon both OX40L-JAG1 
and anti-CD3/CD28 treatment. However, unlike anti-CD3/CD28 treatment which also induced very strong Teff 
cell proliferation, OX40L-JAG1 treatment induced selective proliferation of Tregs without significant Teff prolif-
eration. Analyses of activation markers expression showed a significant (***p < 0.001) increase in the percentage 
of Teff cells expressing CD25, CD44 and CD69 upon treatment with anti-CD3/CD28 compared to control cells 
(Fig. 2B–D). However, no significant difference was observed between the control and OX40L-JAG1 treated Teff 
cells. Moreover, Tregs from both OX40L-JAG1 and anti-CD3/CD28 treated cells had increased CD25, CD44 and 
CD69 expressing cells compared to control cells. These results suggested that soluble OX40L-JAG1 can cause 
selective proliferation of Tregs, without significantly affecting Teff cell activation and proliferation.
Soluble OX40L-JAG1 treatment selectively induces Treg proliferation in vivo. To examine 
whether soluble OX40L-JAG1 can cause in vivo proliferation of Tregs, we treated 10 week-old pre-diabetic NOD 
mice with soluble OX40 L and JAG1 for 3 weeks and analyzed Treg numbers in their spleen, pancreatic and 
peripheral lymph nodes (LN). We did not treat these mice with exogenous IL-2 as we expected IL-2 required 
for Treg survival to be available in vivo. As shown in Fig. 3A,B, we found significantly increased percentages of 
Tregs in the spleen (**p < 0.01), pancreatic LNs (**p < 0.01) and peripheral LNs (***p < 0.001) of OX40L-JAG1 
treated mice compared to PBS treated control mice. Furthermore, to demonstrate OX40L-JAG1 induced Treg 
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proliferation in vivo, we analyzed Ki67 expression in CD4 + Foxp3- (Teff), and CD4 + Foxp3+ (Treg) cells from 
PBS and OX40L-JAG1 treated mice. As shown in Fig. 3C,D, OX40L-JAG1 treated mice had significantly increased 
percentage of Ki67+ cells only in Tregs (**p < 0.01) but not in Teff population when compared to PBS treated 
mice. These results showed that OX40 L and JAG1 can induce preferential proliferation of Tregs both ex vivo and 
in vivo. Further, we treated MHC class-II deficient mice with soluble OX40L-JAG1 to determine whether these 
ligands can increase Tregs in vivo in the absence of canonical antigen presentation through MHC class-II. These 
mice also had reduced CD4+ T-cells and increased number of CD8+ Foxp3+ T-cells when compared to wild 
type mice (data not shown). OX40L-JAG1 treatment significantly increased CD4 + Foxp3 + Tregs (**p < 0.05) 
and CD4-Foxp3+ T-cells (**p < 0.01) in these mice compared to PBS treated control mice (Fig. 3E,F). These 
results indicated that soluble OX40L-JAG1 can induce selective proliferation of Tregs in vivo independent of 
canonical antigen presentation to TCR.
OX40L-JAG1-IL-2 expanded Tregs retain stable-suppressive phenotype and delay the onset of 
diabetes in NOD mice. Next we examined whether these OX40L-JAG1 expanded Tregs retained their sup-
pressive phenotype and functions. We analyzed the expression of suppressive markers such as CTLA4, CD39, 
Helios and TIGIT in Tregs from control and OX40L-JAG1 treated mice. As shown in Fig. 4A,B, OX40L-JAG1 
expanded Tregs had significantly increased expression of suppressive markers such as CTLA4 (***p < 0.001), 
Figure 1. G-BMDC-induced Treg proliferation in NOD mice is mediated through OX40L-JAG1  
co-signaling. (A) CD4+ T-cells were co-cultured with either splenic DCs or G-BMDCs in 1:1 ratio for 5 
days. Extent of Treg proliferation was analyzed by flow cytometry based on cell trace violet dilution. Numbers 
in upper right and left quadrants indicate percentages of resting and proliferating Treg cells. (B) Bar graph 
showing percentages of resting (Black) and proliferating (Grey) Tregs. Values are expressed as Mean ± SEM 
(n = 3; ***p < 0.001 Vs splenic DCs). (C) G-BMDCs were pretreated with indicated blocking antibodies 
(High = 10 μgml, Low = 5 μ g/ml) for 2 hrs, co-cultured with CD4+ T-cells and extent of Treg cell proliferation 
was measured by flow cytometry as mentioned for Fig. 1A. (D) Bar graph showing effect of blocking antibodies 
on G-BMDC induced Treg proliferation. Values are expressed as Mean ± SEM (n = 3; **p < 0.01 Vs None).(E) 
CD4+ T-cells were treated with combinations of soluble OX40 L (5 μ g/ml), JAG1 (5 μ g/ml) and IL-2 (10IU/ml) 
for 3 days as indicated. Treg proliferation was assayed by flow cytometry based on cell trace violet dilution. (F) 
Bar graph showing percentages of resting and proliferating Tregs from three independent experiments. Values 
are expressed as Mean ± SEM (n = 3; *p < 0.05, **p < 0.01 Vs IL-2).
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Figure 2. Soluble OX40L-JAG1 can cause selective Treg proliferation independent of TCR stimulation. 
(A) CD4+ T-cells were treated with IL-2 (Control), OX40L-JAG1-IL-2 and anti-CD3/CD28-IL-2 for 3 days. 
Extent of CD4+ Foxp3- (Teff) and CD4+ Foxp3+ (Treg) cell proliferation was analyzed by flow cytometry. 
(B) From the above experiments, percentages of CD25, CD44 and CD69 expressing Teff (Grey) and Treg 
(Black) cells were gated and indicated as numerical. (C,D) Bar graph showing percentages of Teff cells and Treg 
cells expressing CD25, CD44 and CD69. Values are expressed as Mean ± SEM (n = 3; *p < 0.05, **p < 0.01, 
***p < 0.001 Vs control).
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Helios (***p < 0.001) and TIGIT (**p < 0.01) when compared to control Tregs. CD39 expression was not sig-
nificantly different between control and OX40L-JAG1 expanded Tregs. Furthermore, we setup an ex vivo sup-
pression assay using control Tregs and OX40L-JAG1 expanded Tregs to confirm the functional competency of 
OX40L-JAG1-IL-2 expanded Tregs. In line with the phenotypic results, we found OX40L-JAG1 expanded Tregs to 
efficiently suppress Teff proliferation similar to control Tregs (Fig. 4C,D). Taken together, these results suggested 
that OX40L-JAG1 could expand functional Tregs without loss of their suppressive phenotype and function.
Next, we treated NOD mice with soluble OX40 L and JAG1 once a week at 10–12 weeks of age and monitored 
their blood glucose levels. As shown in Fig. 5A, by 27th week 100% of control mice became hyperglycemic, while 
Figure 3. Soluble OX40L-JAG1 can cause Treg proliferation in vivo. (A) Ten week old NOD mice were 
treated with either PBS or 100 μ g of OX40 L and JAG1 once a week for three weeks. Two weeks later, mice were 
sacrificed and Treg cell numbers in spleen, pancreatic LNs and peripheral LNs were analyzed. Upper and lower 
panels show percentages of Tregs in PBS and OX40L-JAG1 treated mice respectively. Numerical in upper right 
quadrant indicates percentages of Foxp3 Tregs. (B) Bar graph showing percentages of Treg in spleen, pancreatic 
and peripheral lymph nodes of PBS (Grey) and OX40L-JAG1 (Black) treated mice. Values are expressed as 
Mean ± SEM (n = 3; **p < 0.01, ***p < 0.001 Vs PBS). (C) Splenocytes from PBS and OX40L-JAG1 treated mice 
were stained for CD4, Foxp3 and Ki67 (proliferation marker). Ki67+ cells among CD4+ Foxp3- (Grey-Teff) 
and CD4+ Foxp3+ (Black-Treg) cells were gated and shown as histograms. (D) Bar graph summarizing results 
shown in Fig. 3C. Values are expressed as Mean ± SEM (n = 3; **p < 0.01 Vs PBS). (E) MHC Class-II−/− mice 
were treated with either PBS or 100 μ g of OX40 L and JAG1 as mentioned above and Treg numbers in spleens 
were analyzed. Numbers in the quadrants indicate percentages of CD4-Foxp3+ , CD4+ Foxp3+ and CD4+ 
Foxp3-T-cells. (F) Bar graph showing percentages of above mentioned cell types in spleens of PBS (Grey) and 
OX40L-JAG1 (Black) treated mice. Values are expressed as Mean ± SEM (n = 3; *p < 0.05, **p < 0.01 Vs PBS).
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40% of OX40 L and JAG1 treated mice were still normoglycemic (*p < 0.05). Additionally, we found significantly 
higher percentages of Tregs in the spleen of OX40 L and JAG1 treated mice (15.87 ± 0.80) relative to controls 
(10.67 ± 1.83; *p < 0.05, n = 10) (Fig. 5B). Examination of the pancreatic sections showed that OX40 L and JAG1 
treated mice had more number of intact islets and reduced incidence of peri-insulitis (Fig. 5C). Nearly 70% of the 
islets from control mice showed severe insulitis with only 7.14% exhibiting normal architecture. In contrast, only 
30% of the islets from OX40 L and JAG1 treated mice showed heavy infiltration and over 30% of the islets exhib-
ited normal architecture (Fig. 5D). OX40 L and JAG1 treated mice also had higher proportion of insulin secreting 
islets relative to control mice (Fig. 5E). Further, we stimulated splenocytes from control and OX40L-JAG1 treated 
mice with PMA-Ionomycin, and analyzed their cytokine expression profile by RT-qPCR. We found reduced 
expression of Th1 cytokines such as IFN-γ , IL-12α (*p < 0.05), IL-12β (**p < 0.01) and TNF-α (*p < 0.05), and 
increased expression of Th2 cytokines such as IL-4 (**p < 0.01) and IL-13 (*p < 0.05) in the splenocytes from 
OX40L-JAG1 treated mice relative to controls (Fig. 5F) upon stimulation. We also noted increased expression of 
anti-inflammatory cytokine IL-10 (**p < 0.01) and pro-inflammatory cytokine IL-6 (**p < 0.01) in splenocytes 
from OX40 L and JAG1 treated mice. A recent study has shown that transgenic expression of Notch1 intracellular 
domain in Treg cells can cause lymphoproliferation, exacerbated Th1 responses and autoimmunity30. To see if a 
similar phenomenon was occurring, we stimulated splenocytes from control and OX40L-JAG1 treated mice with 
PMA-Ionomycin and stained both Treg and Teff cells for IFN-γ expression. Our results clearly showed that there 
was no change in the percentage of IFN-γ expressing Teff cells between control and OX40L-JAG1 treated mice, 
and there was barely any IFN-γ expressing Tregs in both control and OX40L-JAG1 treated mice (Fig. S3).
Soluble OX40L-JAG1-IL-2 induced Treg proliferation is mediated through activation of OX40, 
Notch and IL-2R mediated NF-κB and STAT5 signaling pathways. Subsequently, we analyzed for 
differential mRNA expression between resting and proliferating Treg cells to gain insights into the signaling 
Figure 4. Phenotypic characterization of OX40L-JAG1-IL-2 expanded Treg cells and in vitro suppression 
assay. (A) Control (grey) and OX40L-JAG1 (black) expanded Treg cells were analyzed for the expression of Treg 
suppressive markers such as CTLA4, CD39, Helios and TIGIT and CD25 by FACS analysis. Numerical indicate 
respective MFI values of CTLA4, CD39, Helios and TIGIT expression in control Vs OX40L-JAG1 expanded 
Treg cells (n = 3). (B) Bar graph summarizing results showin Fig. 7A (Values represent Mean ± SEM, n = 3, 
**p < 0.01, ***p < 0.001 Vs Control) (C) Control and OX40L-JAG1 expanded CD4+ CD25+ Treg cells from 
NOD mice were co-cultured with cell trace violet labeled fresh CD4+ CD25- Teff cells at indicated ratios and 
stimulated with anti-CD3/CD28 for 3 days. Extent of Teff proliferation was measured by flow cytometry. (D) 
Percentage of suppression was calculated as ratio between proliferating Teff cells from Treg:Teff co-cultures to no 
Treg control. Graph summarizing % of suppression calculated from 4 C (Values represent Mean ± SEM, n = 4).
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pathways activated in proliferating Tregs. As shown in Fig. 6A, proliferating Tregs showed higher levels of expres-
sion of Treg functional markers such as Ctla4, Ikzf2 (Helios), Ikzf4 (Eos), Tigit, Entpd1 (CD39), Foxp3, Gzmb, 
Icos, Tgfb1 and themis; and functional partners of Foxp3 such as Bcl11b, Bclaf1, Cbfb, Runx1, Yy1, Bax, Cebpz, 
Cnot3, Gata3, Max, Nacc1 and Trp53. Additionally, we noted increased expression of genes associated with OX40 
Tnfrsf4 (OX40), Bcl10, Prkcq (PKC-θ ); Notch (Dlgap, Dnajc19, Foxp3, Rbpi); and IL-2R mediated signaling (Il-2ra, 
Il-2rb, Il-2rg and Stat5b) in proliferating Tregs, indicating the importance of signaling through these receptors. 
Furthermore, we also observed increased expression of NF-κ B related genes such as NF-κB1, NF-κB2, RelA and 
RelB in proliferating Tregs. We validated our micro-array results in a candidate gene approach by RT-qPCR anal-
ysis and observed significantly elevated expressions of OX40, Prkcq, Foxp3, Dlgap, Il-2ra (Cd25), NF-κB1 and 
NF-κB2 in proliferating Tregs (Fig. 6B). Besides, we analyzed the mean fluorescence intensities of CTLA4, CD39, 
OX40, CD25 and Foxp3 expression between resting and proliferating Tregs by flow cytometry. As shown in 
Fig. 6C, consistent with our microarray and RT-qPCR results, proliferating Tregs had increased expression of all 
these suppressive markers when compared with resting Tregs.
OX40 L has been shown to bind to its only known cognate receptor OX40, constitutively expressed on Tregs31. 
However, JAG1 can bind to multiple receptors such as Notch1, Notch232 and Notch333 of which Notch3 is prefer-
entially up-regulated in Tregs29,34. Additionally, JAG1 has been characterized as the most abundant and specific 
ligand for Notch333.Therefore, we hypothesized that loss of either OX40 or Notch3 might negatively affect Treg 
Figure 5. Treatment of NOD mice with OX40L-JAG1 delays onset of diabetes. (A) NOD mice were 
administered with OX40 L and JAG1 once a week for 10–12 weeks. After OX40L-JAG1 treatment blood glucose 
level was monitored weekly. Kaplan-Meier survival graph shows significantly delayed onset of diabetes in NOD 
mice upon OX40L-JAG1 treatment (*p < 0.05 Vs PBS-treated). (B) Spleens of 28 week old PBS and OX40-JAG1 
treated NOD were analyzed for the percentage of CD4+ Foxp3+ Treg cells by flow cytometry. (B) Bar graph 
summarizing % of Tregs in spleens of PBS and OX40L-Jag1 treated mice after 28 weeks. Values are expressed 
as Mean ± SEM (n = 10, *p < 0.05). (C) H & E staining analysis of pancreatic sections from PBS and OX40L-
JAG1 treated NOD mice (n = 10).(D) Insulitis scoring was done as described in materials & methods with the 
following scoring scheme: 0-no insulitis, 1-peri-islet insulitis, 2-intermediate insulitis, 3-intraislet insulitis, 
4-complete islet insulitis. (E) Pancreatic sections were stained for insulin by immunohistochemistry (n = 10). 
(F) Splenocytes from PBS and OX40L-JAG1 treated mice were stimulated with PMA/Ionomycin and mRNA 
expression of indicated cytokines was analyzed by RT-qPCR. Expression values are expressed as fold induction 
over stimulated control cells after normalization with GAPDH. (Values represent Mean ± SEM, n = 7, *p < 0.05, 
**p < 0.01).
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proliferation induced by OX40 L, JAG1 and IL-2. We treated CD4+ T-cells isolated from OX40−/−, Notch3−/− and 
respective wild type C57BL6 and B6129SF1 control mice with soluble OX40 L, JAG1 and IL-2 for 3 days. As 
shown in Fig. 7A,B, we noted a significantly lower percentage of proliferating Tregs from OX40−/− (***p < 0.001) 
and Notch3−/− (*p < 0.05) mice compared to their corresponding wild type controls. Further, we treated wild 
type, OX40−/− and Notch3−/− mice with soluble OX40 L and JAG1 for 3 weeks and analyzed Treg numbers in 
the spleen. As shown in Fig. 7C–E, we did not observe any significant difference in the total number of splenic 
Tregs among untreated OX40−/−, Notch3−/− and the corresponding wild type control mice. Similarly, basal Foxp3 
expression was also not significantly different among OX40−/−, Notch3−/− and corresponding wild type control 
mice (Fig. S4). However, treatment with soluble OX40L-JAG1 caused a significant (***p < 0.001) increase in Treg 
numbers in both C57BL6/J and B6129SF1/J wild type mice, but not in OX40−/− mice. In OX40L-JAG1 treated 
Notch3−/− mice there was a significant increase of Tregs compared to PBS-treated Notch3−/− mice (*p < 0.05), 
but the level of increase was still significantly less than wild type mice treated with OX40L-JAG1 (*p < 0.05 Vs 
OX40L-JAG1). These results suggested that although expression of OX40 or Notch3 is not required for the devel-
opment of Tregs or Foxp3 expression in steady state, they are indispensable for optimal Treg proliferation induced 
by OX40 L and JAG1.
Since our micro array results suggested upregulation of genes associated with NF-kB and STAT5 signaling in 
proliferating Tregs compared to resting Tregs, we examined their role in TCR independent Treg proliferation. 
As shown in Fig. 8A, OX40 L, JAG1 and IL-2-induced Treg proliferation was significantly blocked by NF-κ B and 
STAT5 inhibitors, but not by MEK inhibitor. Next, we investigated whether NF-κ B and STAT5 signaling pathways 
were involved in the regulation of Foxp3 expression using RT-qPCR (Fig. 8B) and Western blot (Fig. 8C). While 
Figure 6. Differential gene expression analysis of resting and proliferating Treg cells. (A) Resting and 
proliferating Treg cells were sorted out based on Cell Trace violet dilution and subjected to microarray 
analysis to probe the differential gene expression pattern between these cells. Respective heat maps show the 
significantly altered expression of surface molecules, Treg functional markers, functional partners of Foxp3 
and signaling molecules. (B) Validation of micro array results in a candidate gene approach by RT-qPCR. 
Fold induction values over resting Treg cells were expressed as Mean ± SEM (n = 3, *p < 0.05, **p < 0.01, 
***p < 0.001 Vs Resting). (C) Resting and proliferating Treg cells stained for OX40, CTLA4 (CD152), CD25, 
CD39 and Foxp3. Respective MFI values of resting (Grey) and proliferating (black) Treg cells are indicated.
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Figure 7. Characterization of OX40L-JAG1 induced Treg proliferation in OX40−/− and Notch3−/− mice. 
(A) Extent of Treg proliferating induced by OX40L-JAG1-IL-2 was compared between C57BL6 wild type (black) 
Vs OX40− /− mice (grey), and B6129SF1 wild type (black) Vs Notch3− /− (grey) mice. Numerical represent 
percentages of proliferating Treg cells. (B) Bar graph summarizing results shown in (A). Values are expressed as 
Mean ± SEM (n = 3; *p < 0.05, ***p < 0.001 Vs respective wild type controls). (C) C57BL6 wild type, OX40−/−, 
B6129SF1 wild type and Notch3−/− mice were treated with soluble OX40 L and JAG1 as mentioned in Fig. 3A. 
Spleens were analyzed for Treg cell numbers. Upper and lower panels show percentages of Tregs in PBS and 
OX40L-JAG1 treated mice. Numbers in upper right quadrant indicate percentages of Foxp3 Tregs (n = 3). (D,E) 
Bar graphs (D,E) show percentages of Tregs in C57BL6-WT Vs OX40−/− and B6129SF1-WT Vs Notch3−/− mice 
treated with either PBS control or OX40L-JAG1 (*p < 0.05, ***p < 0.001 Vs WT-control; #p < 0.05, ###p < 0.001 
Vs OX40−/− or Notch3−/− OX40L-JAG1).
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OX40 L, JAG1 and IL-2-induced Foxp3 expression was significantly down regulated in the presence of NF-κ B 
inhibitor, whereas it was only moderately inhibited in the presence of a STAT5 inhibitor at 24 h.
Next, we carried out a time course analysis to determine the effect of OX40 L, JAG1 and IL-2 on Foxp3 
expression, and NF-κ Bp65 and STAT5 activation. We observed a significant increase in Foxp3 expression at 
24 h (*p < 0.05) which was sustained up to 120 h (Fig. 8D). While phospo-NF-κ Bp65 levels were maximal at 
24 h (**p < 0.01) (Fig. 8E), STAT5 phosphorylation was maximum at 72 h (***p < 0.001, **p < 0.01) (Fig. 8F). 
Thus, it appears that Foxp3 expression was initially induced by NF-κ Bp65 phosphorylation and later sustained 
by STAT5 activation. Next, we treated CD4+ T-cells with different combinations of OX40 L, JAG1 and IL-2 and 
analyzed for Foxp3 expression, and NF-κ Bp65 and/or STAT5 activation. A combination of OX40 L, JAG1 and 
IL-2 caused maximum Foxp3 expression (**p < 0.01), followed by the combinations of OX40L-IL-2, JAG1-IL-2 
and OX40L-JAG1 (Fig. 8G). Intriguingly, a significant increase in NF-κ Bp65 activation was observed only upon 
OX40 L co-treatment with JAG1 (**p < 0.01) or IL-2 or both (***p < 0.001) (Fig. 8H). Similarly, we observed 
impaired activation of NF-κ Bp65, in OX40−/− CD4+T-cells upon OX40L-JAG1-IL-2 treatment while STAT5 acti-
vation remained unaffected (Fig. S5). Altogether, these results suggested that Treg proliferation might involve 
upstream signaling through OX40, Notch3 and IL-2R receptors followed by the activation of downstream NF-κ B 
and STAT5 signaling pathways.
Figure 8. Role of NF-κB and STAT5 signaling pathways in OX40L-JAG1-IL-2 induced Treg proliferation 
and Foxp3 expression. (A) CD4+ T-cells from NOD mice were pre-treated with pharmacological inhibitors of 
indicated cell signaling pathways and treated with soluble OX40L-JAG1-IL-2. Effect of these pathway inhibitors 
on Treg cell proliferation was measured by flow cytometry analysis. (B) RT-qPCR analysis showing effect of 
inhibitors of NF-κ B and STAT5 signaling pathways on Foxp3 mRNA expression (Values represent Mean ± SEM, 
n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 Vs control, #p < 0.05, ##p < 0.01 Vs None-OX40L-JAG1-IL-2).  
(C) Western blot analysis showing effect of inhibitors of NF-κ B and STAT5 signaling pathways on Foxp3  
protein expression. Western blot analysis of the time dependent effect of soluble OX40L-JAG1-IL-2 on  
(D) Foxp3 expression, (E) NF-κ B p65 phosphorylation and (F) STAT5 phosphorylation in CD4+ T-cells. 
Western blot analysis of the effects of permutation combinations of soluble OX40 L, JAG1 and IL-2 on  
(G) Foxp3 expression, (H) NF-κ B p65 phosphorylation, and (I)STAT5 phosphorylation in CD4+ T-cells 
(Values represent Mean ± SEM, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 Vs Control).
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Discussion
Growing body of evidence demonstrates the protective role for Foxp3+ Tregs in various autoimmune diseases6,7,35. 
However, translation of Treg cell therapy to clinical settings is impeded by several limitations. One of these limi-
tations is the inability of TCR-dependent approaches to cause selective in vivo expansion of Tregs10. Unlike stim-
ulation with anti-CD3/CD28 which activated both Tregs and Teff cells, stimulation with OX40L-JAG1 caused 
selective proliferation of Tregs without activating Teffs as evidenced by no significant change in the expression 
of activation markers such as CD25, CD44 and CD69 on Teff cells. Differential gene expression analysis between 
resting vs proliferating Tregs showed up-regulation of expression of Foxp3 and its functional partners Gata3, 
Runx1, Cnot3, Cbfb, Cebpz and Bcl11b in proliferating Tregs. These molecules are known to increase the func-
tional fitness of Tregs. For example, expression of Gata3 by Tregs is essential for their migration towards the site of 
inflammation and to sustain Foxp3 expression under inflammatory conditions36. Runx and CBF-β complex have 
been shown to directly bind to Foxp3 promoter and increase its transcription37. Similarly, transcription factor 
Bcl11b can bind to both Foxp3 and IL-10 promoters, and regulate their expression and help confer Treg mediated 
protection against IBD38. Besides, we observed up-regulation of Ctla-4, Helios, Tigit, Icos, Cd39, Pdcd1 and Tgf-β1, 
all of which are suppressive and stable phenotypic markers of Tregs. Further, in vivo treatment of NOD mice with 
soluble OX40 L and JAG1 resulted in a significant increase of Tregs. We also found increased expression of sup-
pressive markers such as CTLA-4, Helios and TIGIT in Tregs expanded by in vivo treatment with OX40L-JAG1. 
CD39 expression was comparable between control and OX40L-JAG1 expanded Tregs. CTLA-4 is one of the most 
widely accepted mediators of Treg suppressive functions35. CD39, an ectonucleotidase that can hydrolyze ATP, 
is considered as a stability marker for Tregs and CD39+Foxp3+ Tregs have been shown to suppress both Th1 and 
Th17 cells39. TIGIT is another Treg cell specific co-inhibitory molecule. TIGIT+ subset of Tregs have been shown 
to predominantly inhibit Th1 and Th17 cells without affecting Th2 cells40. Helios, an Ikoras transcription factor 
family member, has also been reported to be associated with Treg functions41 and suppression of autoimmune 
diabetes42. Increased expression of these suppressive markers in OX40L-JAG1 expanded Tregs could help sustain 
their suppressive functions. Besides, we also confirmed the functional competency of these expanded Tregs in 
ex vivo suppressive assays.
Intriguingly, treatment of NOD mice with either OX40 L or JAG1 alone failed to significantly alter the course 
of diabetes (data not shown). We and others have observed that treatment of 6-week old NOD mice with either 
OX40 L or an anti-OX40 agonistic antibody (OX86) can increase CD4+CD25+Foxp3+Treg cells and protect 
NOD mice from developing diabetes43,44. However, treating 12-week old NOD mice with OX40 L accelerated 
diabetes development likely due to an increased pro-inflammatory environment associated with aging in these 
mice44. Thus, the outcome of treatment with OX40 L alone appears to be age-dependent in NOD mice. In con-
trast, co-treatment of 10–12-week old NOD mice with OX40 L and JAG1 significantly increased functional Treg 
numbers and delayed the onset of diabetes. These results indicated a critical requirement for co-signaling induced 
by OX40 L and JAG1 to increase and sustain functionally competent Tregs. It should be noted that we treated mice 
with OX40L-JAG1 once a week for only three weeks near the time of diabetes onset. However, repeated follow-up 
treatments might yield better results. Additionally, IL-2 deficiency in older NOD mice might have also led to 
poor survival of expanded Tregs45 and thus supplementation with IL-2 might have also increased the longevity of 
expanded Tregs. Interestingly, splenocytes from OX40 L and JAG1 treated mice upon PMA-Ionomycin stimula-
tion showed reduced expression of inflammatory cytokines i.e. IFN-γ , IL-12α , IL-12β and TNF-α and increased 
expression of anti-inflammatory cytokines such as IL-10, IL-4 and IL-13 relative to controls. Previous reports 
have demonstrated the protective effects of anti-inflammatory cytokines such as IL-4, IL-10 and IL-13 in autoim-
mune diabetes46–48. Together, these results suggested that OX40 L and JAG1 co-treatment might have restored the 
balance between anti- and pro-inflammatory cytokines, and created a favorable cytokine milieu in which Tregs 
could proliferate and retain their suppressive functions. This notion is further evident from the reduced incidence 
of severe insulitis and preservation of more numbers of intact insulin secreting islets in OX40 L and JAG1 treated 
mice. However, further studies are required to optimize the therapeutic efficacy of this treatment.
In general, signaling required for Treg proliferation is primarily understood in the context of TCR stimulation. 
Previously, it has been reported that engagement of TCR with anti-CD3/CD28 can induce ZAP70, PI3K, Akt 
and MAPK signaling and activation of transcription factors NFAT, c-Jun, NF-κ B and AP149. However, the sign-
aling that drives TCR-independent Treg proliferation is not well defined. Interestingly, while OX40L-JAG1-IL-2 
induced Treg proliferation was significantly abrogated in OX40−/− and Notch3−/− mice, Treg proliferation 
induced by TCR stimulation remained unaffected in these mice (data not shown). Additionally, differential 
gene expression analysis revealed selective activation of genes associated with OX40, Notch and IL-2R receptor 
signaling in proliferating Tregs. Collectively, these results showed that the ligation of OX40 L and JAG1 with 
their cognate receptors OX40 and Notch3 are the major upstream events regulating this TCR-independent Treg 
proliferation.
The relevance of OX40 L induced signaling in Treg expansion and function has remained elusive. OX40 
expression has been shown to be essential for Treg migration to inflamed sites50–52. While OX40L-OX40 stim-
ulation can cause Treg proliferation, it could also adversely affect Foxp3 expression and Treg suppressive func-
tions depending upon the local cytokine milieu53,54. During TCR stimulation OX40L-OX40 interaction has been 
shown to activate PI3K (PI-3-kinase)/PKB (protein kinase B/Akt) and NF-κ B1 pathways55,56. Two members of 
the TRAF family of proteins such as TRAF2 and TRAF5 have been identified as key adaptor proteins recruited 
by OX40 to drive NF-kB1 activation57. In the absence of TCR stimulation, OX40 has been shown to form a sig-
nalosome containing TRAF2, CARMA1, MALT1, BCL10, PKCθ , RIP and IKKα /β /γ to cause NF-kB activation 
required for T-cell survival58. Our results showed that activation of NF-kB by OX40L-OX40 is indispensable for 
Treg proliferation in the absence of TCR-stimulation. OX40 deficient Tregs showed impaired NF-kB activation 
as well as proliferation induced by OX40L-JAG1. Several lines of evidence suggest that Notch signaling plays 
a positive role in Treg homeostasis by increasing Treg numbers in thymus and periphery, and by maintaining 
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Foxp3 expression34,59,60. In particular, Notch3 has been shown to positively regulate nTreg development and Foxp3 
expression34. It has been shown that Notch3 and canonical NF-κ B signaling pathways could co-operatively reg-
ulate Foxp3 expression61. Hence, JAG1 induced Notch3 signaling, along with transactivation of NF-κ B-p65 by 
OX40 L, could co-operatively regulate Treg proliferation and Foxp3 expression.
The role of IL-2 induced STAT5 signaling in Treg survival and stable Foxp3 expression is well established62. 
Foxp3 promoter has a STAT5 binding site63 through which Foxp3 expression is regulated in both human and 
mouse Tregs64. In addition, Foxp3 gene has a T-Cell Specific Demethylated Region (TSDR) in its promoter which 
can be demethylated through IL-2/STAT5 signaling to sustain Foxp3 expression65,66. Consistent with these earlier 
findings, we noted enhanced Foxp3 expression upon addition of IL-2. Thus, enhanced activation of NF-κ Bp65 
by OX40 L and JAG1, and STAT5 signaling by IL-2 likely promoted Treg proliferation with sustained Foxp3 
expression in the absence of TCR signaling. However, further studies are needed to fully understand the intri-
cate signaling mechanisms involved in OX40L-JAG1-IL-2 induced Treg proliferation. In summary, our findings 
demonstrate that OX40L-JAG1 co-signaling can cause selective proliferation of Tregs in a TCR-independent 
mechanism which will have potential utility in treating autoimmune diseases. This TCR-independent Treg pro-
liferation and Foxp3 expression is critically dependent on NF-kB signaling induced by OX40L-JAG1 and STAT5 
signaling induced by IL-2.
Materials and Methods
Animals. NOD, C57BL/6 J, B6129SF1/J, OX40 and Notch3 deficient mice were purchased from Jackson 
Laboratories. MHC class-II deficient mice (ABBN12 (H2-Ab1)) were from Taconic biosciences. Breeding col-
onies were established and maintained in a pathogen-free facility of the biological resources laboratory (BRL) 
of the University of Illinois at Chicago (Chicago, IL). All animal experiments were approved and performed 
in accordance with the guidelines set forth by the Animal Care and Use Committee at University of Illinois at 
Chicago.
Isolation of T-cells, and G-BMDCs-T-cells co-cultures. Spleens were excised and single cell suspensions 
were prepared and over 90% pure total CD4+ T-cells and CD4+CD25+ Tregs were isolated according to the man-
ufacturer’s protocol (Miltenyi Biotech, CA). To derive G-BMDCs, cells isolated from femoral bones were cultured 
in complete RPMI-1640 containing 10% FBS supplemented with GM-CSF (20 ng/ml) for seven days. From this 
culture CD11c+ G-BMDCs were sorted and co-cultured with Cell-Trace Violet (Life technologies) labeled CD4+ 
T-cells at 1:1 ratio for five days. For TCR stimulation, cells were cultured in anti-CD3 (2 μ g/ml) coated plates in 
the presence of anti-CD28 (2 μ g/ml) (eBioscience) and IL-2 (50 IU/ml) for 72 h. In some experiments splenocytes 
and CD4+ T-cells (1 × 106 /ml) were treated with recombinant mOX40 L (5 μ g/ml) and mJAG1 (1 μ g/ml) and 
mIL-2 (10 IU/ml) for 24–120 h. For proliferation experiments splenocytes and CD4+ T-cells were stained with 
Cell-Trace violet and then treated with OX40L-JAG1-IL-2.
RNA Isolation, Micro-array and RT-qPCR analyses. Resting and proliferating Tregs were sorted based 
on cell trace violet dilution. Total RNA was isolated from these cells by using RNAeasy columns (Qiagen). The 
cDNA synthesized from total RNA was used for RT-qPCR analysis with Fast SYBR green master mix (Applied 
Biosystems) and gene specific primers (listed in supplementary table-1) by using AB ViiA7 RT-qPCR instrument 
(Applied Biosystems). Gene expression values were calculated by comparative Δ Ct method after normalization 
to GAPDH internal control and expressed as fold change over respective controls.
Micro array analysis was performed in duplicate using the Affymetrix GeneChip Mouse Genome 430 2.0 
microarray at Center for genomics core facility, University of Illinois at Chicago. Briefly, biotinylated cDNA was 
synthesized from total RNA using biotinylated dNTPs and allowed to hybridize with microarrays and scanned. 
Arrays which passed quality control tests were further subjected to gene expression analysis after normalization 
with housekeeping gene controls. Data were analyzed using the R-package software. Student’s t-test was used to 
filter differentially expressed genes Micro array has been submitted to NCBI-Gene Expression Omnibus database 
and publicly available (Accession No. GSE81051).
Western blot. CD4+ T- cells (1 × 106 cells/ml) were treated with soluble OX40 L, JAG1 and IL-2 as 
mentioned above. In some experiments cells were pre-treated with inhibitors of Notch (GSI-RO4929097, 
Selleckchem), NF-κ B (BAY-11–7082, Sigma-Aldrich) and STAT5 (CAS 285986-31-4, Calbiochem) signaling for 
2 h and co-treated with soluble ligands for different time intervals. Cells were washed with PBS, and lysed in 
Laemmli buffer (Biorad) and resolved in 10% SDS-PAGE gels. Proteins were transferred to PVDF membranes 
(Biorad), blocked with 5% skimmed milk and incubated with primary anti-mouse Foxp3 (1:1000, e-bioscience), 
anti-mouse phospho p65 (Ser536) and phospho STAT5 (Tyr694) (1:500, Cell Signaling Technology) antibodies. 
Blots were then washed, incubated with secondary anti-rabbit IgG-HRP and developed using ECL detection kit 
(Pierce Scientific). Blots were stripped and re-probed with anti-mouse β -actin-HRP antibody (1:5000; Santacruz 
Biotechnology), anti-mouse p65 and STAT5 (1:500, Cell Signaling Technology), and developed. Densitometry 
analysis was done using MyImage Analysis software (Thermo Scientific). Foxp3, pp65 and pSTAT5 signal intensi-
ties were normalized to β -actin, total p65 and STAT5 signal intensities and expressed as fold change over respec-
tive controls.
FACS Analysis. For flow cytometry analysis cells were washed with PBS containing 0.5% BSA, either surface 
stained with anti-CD4-eFluor-780, CD4-FITC (eBioscience), anti-CD25-PE, anti-CTLA4-PE, anti-CD39-PE, 
anti-Helios-PE, anti-TIGIT-PE or fixed, permeabilized, and stained with anti-, Anti-Ki67-PE, anti-Foxp3-APC 
and isotype controls antibodies (eBioscience) (1:100) in dark. Samples were analyzed using CyAn ADP Analyzer 
(Beckman and Coulter) and data analysis was done using Summit v4.3 software.
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Suppression Assay. CD4+CD25+ Tregs sorted from control and OX40L-JAG1 treated were co-cultured with 
CFSE-labeled CD4+CD25- Teff cells at 1:16, 1:8, 1:4, 1:2 and 1:1 ratios and stimulated with anti-CD3/anti-CD28. 
Extent of proliferation was measured by cell trace violet dilution and percentage of suppression of Teff cell prolif-
eration was calculated as described previously29.
Cell stimulation and cytokine expression analysis. Splenocytes from PBS and OX40L-JAG1 treated 
mice were stimulated with 500X cell stimulation cocktail (eBioscience) containing PMA and ionomycin with 
protein transport inhibitors for 16–24 h. mRNA expression of cytokines such as IFN-γ , IL-12α , IL-12β , TNF-α , 
IL-4, IL-5, IL-13, IL-10, IL-6 and IL-17 was analyzed by RT-qPCR as described above using primers listed in 
supplementary table-1.
Animal experiments. Six week old female NOD mice were divided into two groups each containing13 
mice. Mice were injected (i.p) with recombinant OX40 L (200 μ g) and JAG1 (200 μ g) on weeks 10, 11 and 12. Age 
and sex matched control mice received PBS. All the reagents used for animal experiments were endotoxin free 
(< 0.1 EU/ml) when tested by using Pierce endotoxin quantification kit (Thermo scientific). Blood glucose levels 
were monitored weekly from week 9 to 28. On week15, three mice from each group were sacrificed and analyzed 
for Treg cell numbers. At the end of week 28, all animals were sacrificed and tissue sections of pancreas were sub-
jected to histopathological examination to determine lymphocyte infiltration and β -cell destruction.
Histopathology and immunohistochemistry. Pancreatic tissues from control and OX40L-JAG1 treated 
NOD mice were excised and fixed in 10% formalin overnight. Tissues were processed and stained with hema-
toxylin and eosin. Images captured in Aperio digital image scanner were analyzed with Aperio Image-scope 
viewer. Insulitis was scored independently by three individuals with the following scoring scheme: 0-no insuli-
tis, 1-peri-islet insulitis, 2-intermediate insulitis, 3-intraislet insulitis, 4 -complete islet insulitis67. For immuno-
histochemistry, sections were stained with anti-Insulin antibody (Abcam, MA), followed by TRITC-conjugated 
anti-guinea pig IgG Abs (T7153) and DAPI (D9542) purchased from Sigma-Aldrich (St. Louis, MO) and sub-
jected to confocal microscopy (Zeiss Laser Scanning Microscope; LSM 710).
Statistical analysis. Statistical analyses were performed using Prism GraphPad (V6.0). Data were expressed 
as Mean ± SEM of multiple experiments. Paired Student’s t-test was used to compare two groups, whereas 
ANOVA with multiple comparisons was used to compare more than two groups. Differences in the frequency of 
hyperglycemia were determined by Kaplan-Meier survival analysis using the log-rank test. A p value < 0.05 was 
considered as significant.
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